Idioma:

Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

Kaseb, A.O. ; Garrett-Mayer, E. ; Morris, J.S. ; Xiao, L. ; Lin, E. ; Onicescu, G. ; Hassan, M.M. ; Hassabo, H.M. ; Iwasaki, M. ; Deaton, F.L. ; Abbruzzese, J.L. ; Thomas, M.B.

Oncology, 2012-01, Vol.82 (2), p.67-74 [Revista revisada por pares]

Basel, Switzerland: Karger

Texto completo disponible

Citas Citado por

Acciones

Título:
Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial
Autor: Kaseb, A.O. ; Garrett-Mayer, E. ; Morris, J.S. ; Xiao, L. ; Lin, E. ; Onicescu, G. ; Hassan, M.M. ; Hassabo, H.M. ; Iwasaki, M. ; Deaton, F.L. ; Abbruzzese, J.L. ; Thomas, M.B.
Materias: Adult ; Aged ; Aged, 80 and over ; Angiopoietin-2 - blood ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Biological and medical sciences ; Biomarkers ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Chemotherapy ; Clinical outcomes ; Clinical Study ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Disease-Free Survival ; Erlotinib Hydrochloride ; Female ; Humans ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Male ; Medical sciences ; Middle Aged ; Oncology ; Pharmacology. Drug treatments ; Proportional Hazards Models ; Quinazolines - administration & dosage ; Quinazolines - adverse effects ; Receptor, Epidermal Growth Factor - blood ; Tumors
Es parte de: Oncology, 2012-01, Vol.82 (2), p.67-74
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descripción: Objective: A phase II study was performed to evaluate the efficacy and tolerability of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) patients, and to investigate clinical and molecular predictors of outcome. Methods: 59 patients with advanced HCC received 10 mg/kg i.v. of bevacizumab every 14 days and 150 mg p.o. of erlotinib daily. The primary endpoint was progression-free survival (PFS) at 16 weeks. Clinical characteristics and plasma biomarkers expression levels were analyzed. Results: PFS at 16 weeks was 64% (95% CI 51–76): 14 patients achieved partial response (24%), 33 had stable disease (56%), 6 progressed (10%), and 6 were not evaluable (10%). Median overall survival was 13.7 months (95% CI 9.6–19.7), and median PFS was 7.2 months (95% CI 5.6–8.3). Grade 3–4 adverse events included fatigue (30%), diarrhea (17%), hypertension (14%), elevated transaminases (12%), and gastrointestinal hemorrhage (10%). High plasma angiopoietin-2, epidermal growth factor receptor, and endothelin-1, and lack of acneiform rash were associated with poor outcome. Conclusions: The combination of bevacizumab with erlotinib achieved encouraging results in patients with advanced HCC. Current correlatives may help to guide future HCC studies.
Editor: Basel, Switzerland: Karger
Idioma: Inglés

Enlaces

Volver a la lista de resultados

Anterior Resultado 9 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

Kaseb, A.O. ; Garrett-Mayer, E. ; Morris, J.S. ; Xiao, L. ; Lin, E. ; Onicescu, G. ; Hassan, M.M. ; Hassabo, H.M. ; Iwasaki, M. ; Deaton, F.L. ; Abbruzzese, J.L. ; Thomas, M.B.

Basel, Switzerland: Karger

Buscando en bases de datos remotas, por favor espere